DrugPatentWatch Database Preview
INLYTA Drug Profile
Email this page to a colleague
See Plans and PricingWhich patents cover Inlyta, and when can generic versions of Inlyta launch?
Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twelve patent family members in fifty-four countries.
The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the axitinib profile page.
US ANDA Litigation and Generic Entry Outlook for Inlyta
Inlyta was eligible for patent challenges on January 27, 2016.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 14, 2030. This may change due to patent challenges or generic licensing.
There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for INLYTA
| International Patents: | 112 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 93 |
| Clinical Trials: | 31 |
| Patent Applications: | 133 |
| Drug Prices: | Drug price information for INLYTA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for INLYTA |
| DailyMed Link: | INLYTA at DailyMed |
Generic Entry Opportunity Date for INLYTA
Generic Entry Date for INLYTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for INLYTA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| M.D. Anderson Cancer Center | Phase 2 |
| BioGene Pharmaceutical Ltd. | Phase 1/Phase 2 |
| Beijing Cancer Hospital | Phase 2 |
Recent Litigation for INLYTA
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Pfizer Inc. v. Glenmark Pharmaceuticals Limited | 2019-06-26 |
| Pfizer Inc. v. Apotex Inc. | 2018-05-25 |
Pharmacology for INLYTA
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Receptor Tyrosine Kinase Inhibitors |
Synonyms for INLYTA
| (E)-N-Methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide |
| (E)-N-methyl-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamide |
| 319460-85-0 |
| 460A850 |
| 4ag8 |
| 4agc |
| 4CA-0215 |
| 790713-39-2 |
| AB0008632 |
| AB01274739_02 |
| AB01274739-01 |
| ABP000115 |
| AC-1539 |
| AC1O51X3 |
| AG 013736 |
| AG-013736 |
| AG-013736;Axitinib |
| AG-13736 |
| AG013736 |
| AG13736 |
| AJ-45709 |
| AK106979 |
| AKOS015902898 |
| AM20090673 |
| AN-501 |
| AOB87786 |
| Axitinib |
| Axitinib (JAN/USAN) |
| Axitinib [USAN:INN:JAN] |
| Axitinib, >=98% (HPLC) |
| Axitinib,AG-013736 |
| Axitinib/AG013736 |
| Axitinib|319460-85-0|AG 013736|AG013736 |
| axitinibum |
| BC659937 |
| BCP01371 |
| BCP9000345 |
| BCPP000372 |
| BDBM25117 |
| Benzamide, N-methyl-2-((3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazo)-6-yl)thio)- |
| Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- |
| BRD-K29905972-001-01-4 |
| BRD-K29905972-001-02-2 |
| C22H18N4OS |
| C9LVQ0YUXG |
| CAS-319460-85-0 |
| cc-356 |
| CHEBI:66910 |
| CHEBI:94568 |
| CHEMBL1289926 |
| CJ-10777 |
| CS-0116 |
| D03218 |
| DB06626 |
| DSSTox_CID_28975 |
| DSSTox_GSID_49049 |
| DSSTox_RID_83240 |
| DTXSID3049049 |
| EX-A337 |
| GTPL5659 |
| HY-10065 |
| I14-1971 |
| Inlyta (TN) |
| J-502064 |
| KB-02558 |
| KB-74537 |
| KS-1448 |
| MFCD09837898 |
| MLS006010164 |
| MolPort-006-392-413 |
| N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide |
| N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide |
| N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide |
| N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide |
| N-methyl-2-({3-[(E)-2-pyridin-2-ylethenyl]-2H-indazol-6-yl}sulfanyl)benzamide |
| N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)-BENZAMIDE |
| N-methyl-2-[[3-[(E)-2-(2-pyridyl)vinyl]-1H-indazol-6-yl]sulfanyl]benzamide |
| N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide |
| NCGC00241108-01 |
| NCGC00241108-04 |
| NCGC00241108-06 |
| NSC-757441 |
| NSC757441 |
| Q-200662 |
| Q-3279 |
| QCR-109 |
| RL03128 |
| S1005 |
| SB20061 |
| SC-22491 |
| SCHEMBL172918 |
| SMR002530046 |
| SR-01000941566 |
| SR-01000941566-1 |
| SW219464-1 |
| SYN1014 |
| Tox21_113597 |
| Tox21_113597_1 |
| TR-013491 |
| UNII-C9LVQ0YUXG |
| ZINC3816287 |
US Patents and Regulatory Information for INLYTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-001 | Jan 27, 2012 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-001 | Jan 27, 2012 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for INLYTA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 200200120 | Start Trial |
| Russian Federation | 2009136593 | Start Trial |
| Montenegro | 00385 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for INLYTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1218348 | 2013/008 | Ireland | Start Trial | PRODUCT NAME: AXITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/777/001 EU/1/12/777/006 20120903 |
| 1218348 | CA 2013 00010 | Denmark | Start Trial | |
| 1218348 | PA2013003,C1218348 | Lithuania | Start Trial | PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
